Search by Drug Name or NDC
NDC 00078-0639-41 COSENTYX 150 mg/mL Details
COSENTYX 150 mg/mL
COSENTYX is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is SECUKINUMAB.
MedlinePlus Drug Summary
Secukinumab injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. It is also used in adults to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin). Secukinumab injection is used in adults to treat ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas, causing pain, swelling, and joint damage). It is also used in adults to treat active non-radiographic axial spondyloarthritis (a condition in which the body attacks the joints of the spine and other areas, causing pain and signs of swelling, but without changes seen on x-ray). Secukinumab is also used in the treatment of enthesitis-related arthritis in children 4 years of age and older. Secukinumab injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.
Related Packages: 00078-0639-41Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Secukinumab Injection
Product Information
| NDC | 00078-0639 |
|---|---|
| Product ID | 0078-0639_3e03ef3f-f697-4301-acc3-f98c22c8ff6b |
| Associated GPIs | 9025057500D530 9025057500D520 9025057500E520 9025057500E530 |
| GCN Sequence Number | 073395 |
| GCN Sequence Number Description | secukinumab PEN INJCTR 150 MG/ML SUBCUT |
| HIC3 | L1A |
| HIC3 Description | ANTIPSORIATIC AGENTS,SYSTEMIC |
| GCN | 37789 |
| HICL Sequence Number | 041715 |
| HICL Sequence Number Description | SECUKINUMAB |
| Brand/Generic | Brand |
| Proprietary Name | COSENTYX |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | secukinumab |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 150 |
| Active Ingredient Units | mg/mL |
| Substance Name | SECUKINUMAB |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Pharmaceutical Class | Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125504 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00078-0639-41 (00078063941)
| NDC Package Code | 0078-0639-41 |
|---|---|
| Billing NDC | 00078063941 |
| Package | 2 mL in 1 CARTON (0078-0639-41) |
| Marketing Start Date | 2015-01-21 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 3587.79 |
| Pricing Unit | ML |
| Effective Date | 2024-01-10 |
| NDC Description | COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |